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Abstract
Multiple sclerosis (MS) is accompanied by decreases in serum endogenous 
enkephalin/endorphins and alterations in inflammatory cytokines. This retrospec-
tive analysis of serum levels was conducted in 53 patients with established relaps-
ing-remitting MS treated with the disease-modifying therapies (DMT) glatiramer 
acetate, dimethyl fumarate or with the biotherapeutic low dose naltrexone (LDN) 
to elevate enkephalins, an off-label alternative. Opioid growth factor (OGF), an 
inhibitory endogenous opioid involved in modulating cellular replication, was mea-
sured and correlated to serum β-endorphin, IL-17A and TNFα. Results revealed that 
MS leads to a significant reduction in OGF levels in subjects on DMTs, but patients 
on LDN had OGF levels comparable to non-MS controls. Individuals on DMTs had 
significantly elevated TNFα levels, while IL-17A levels were significantly elevated 
only in patients taking dimethyl fumarate. A direct correlation was established 
between OGF and IL17A indicating a potential interaction between the OGF-OGFr 
axis and pro-inflammatory T-helper cells providing insight into the disease etiology.
Keywords: relapsing-remitting multiple sclerosis, serum cytokines, opioid growth 
factor, low-dose naltrexone, biomarkers
1. Introduction
Multiple sclerosis (MS) is a demyelinating disorder with an underlying neuroin-
flammatory disease process affecting approximately 2.5 million people worldwide 
[1]. Traditionally, the disease has a greater prevalence in locations which are geo-
graphically north of the equator. In a study from 2015, North America and Europe 
had an average prevalence of greater than 100/100,000 individuals, whereas East 
Asia and Sub-Saharan Africa had rates of 2/100,000 individuals [2].
1.1 Environmental and genetic risk factors
To better understand this disparity, an umbrella systemic review looked at 
the possible environmental risk factors involved in the development of multiple 
sclerosis [3]. An analysis of 44 potential risk factors was filtered down to 3 which 
were found to be profoundly significant: anti-Epstein-Barr Virus Nuclear Antigen 
IgG seropositivity, infectious mononucleosis, and smoking [3]. The hypothesis 
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behind anti-EBVNA IgG suggests that late adolescence exposure to EBV leads to 
infectious mononucleosis with significantly elevated IgG titers when compared to 
individuals who were exposed at a younger age [4, 5]. These titers in turn correlate 
to an increased risk of developing multiple sclerosis. One study done on this, “high-
hygiene” population found that individuals of the same age who were not infected 
with EBV had a 10-fold lower risk of developing multiple sclerosis when compared 
to their EBV infected counterparts [4]. The pathology linking EBV titers to the 
initiation of multiple sclerosis are not yet clear, however it may increase the risk for 
an autoimmune type response as was seen with Systemic Lupus Erythematous and 
EBV [4, 6].
Several studies have shown a direct correlation between cigarette smoking and 
incidence of multiple sclerosis [4, 7–10]. There is some variability in the literature 
between gender and age groups. One study suggests cigarette smoking at a younger 
age (<26.4 years) is associated with a 50% increased risk that was alleviated in 
individuals who were older [8]. A Canadian study comparing gender and smoking 
history and found that 71.5% males diagnosed with multiple sclerosis had previ-
ously smoked compared to 63.6% of females [10]. Smoking has previously been 
defined in several pathologies including cancer, asthma, atherosclerosis and heart 
disease, but within multiple sclerosis, the mechanism is still not understood.
Genetic risk factors have come to the forefront of current research as some have 
been linked with modulation of the immune response. Initial studies linked loci 
of the Major Histocompatibility Complex (MHC) and Human Leukocyte Antigen 
(HLA) as contributing risk in the development and progression of multiple sclerosis 
[4, 11–14]. In particular, HLA-DRB1 and DQB1 gene loci were thought to play a role 
in developing the inherent autoimmunity associated with the disease [11, 14–16].
1.2 Diagnosis of multiple sclerosis
In 2001, the McDonald criteria were created to streamline the diagnosis of 
multiple sclerosis even with its heterogeneous clinical presentation. The initial 
criteria introduced the utility of magnetic resonance imaging (MRI) and integra-
tion of multiple clinical symptoms while removing “clinically definite” and “pos-
sible multiple sclerosis” as alternatives [17]. Since 2001, 3 additional revisions have 
been made to the initial McDonald criteria: 2005, 2010 and 2017 [18–21]. Diagnosis 
of multiple sclerosis is now approached based on dissemination of time (temporal) 
and space. Dissemination in space is defined by either clinical presentation or 
MRI. Clinically, an individual must have symptoms which are distinct to different 
anatomical locations of the central nervous system. Usually, individuals pres-
ent with optic neuritis or ocular symptoms and later acquire gait disturbances or 
peripheral weakness [18, 22]. On MRI, dissemination in space requires T2 evident 
lesions located in at least two distinct zones such as periventricular, infratentorial, 
juxtacortical or within the spinal cord [18, 22]. Dissemination in time requires 
the presence of a gadolinium-enhancing lesion on MRI, indicating an acute or 
active lesion, along with a non-enhancing lesion [18, 22]. The presence of a new 
lesion alone can meet the criteria if it is performed on a follow up scan. Essentially, 
dissemination in time seeks to distinguish multiple sclerosis symptomatology both 
typical and atypical from other neurological disorders which may share certain 
characteristics. As of McDonald 2010, CSF analysis is not required in order to make a 
definitive diagnosis [19–22]. Analysis of CSF typically presents with mildly elevated 
white blood cell count, protein, and IgG oligoclonal bands which are not typically 
seen in serum analysis [22]. IgG oligoclonal bands can be found in 90% of multiple 
sclerosis patients, but it may have a greater role in distinguishing individuals with 
clinically isolated syndrome (CIS) [20]. Some studies demonstrated that CSF 
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oligoclonal bands increase the specificity of MR imaging in adults with CIS and 
pediatrics with radiologically isolated syndrome (RIS) [23, 24]. Beyond the diagnosis 
of multiple sclerosis, CSF analysis may help distinguish other immune mediated 
neurological and non-neurological pathologies.
1.3 Clinical presentation of multiple sclerosis
The disease course of multiple sclerosis is usually defined into four clinical 
subtypes: clinically isolated syndrome (CIS), relapsing-remitting multiple scle-
rosis, secondary progressive multiple sclerosis, and primary progressive multiple 
sclerosis. A majority of patients have a disease course defined by stages of relapses 
and remission which may later translate into the secondary progressive form 
[25]. Clinically, relapses are defined as distinct episodes of neurological dysfunc-
tion which can present as a wide array of symptoms including sensory defects of 
the limbs, visual loss, motor defects, gait disturbances, vertigo, heat sensitivity 
(Uhthoff phenomenon), Lhermitte sign and fatigue [22, 26]. However, multiple 
sclerosis can present atypically in younger individuals, making it difficult to diagno-
sis properly. The initial episodes are followed by periods of remission where the 
patient will fully or partially regain normal function and be deemed neurologically 
stable [27]. In the long term, as some individuals transition from the relapsing-
remitting form to secondary progressive, relapses no longer occur, yet patients will 
experience worsening neurological function [27]. After 10 years of disease, 50% of 
individuals with relapsing-remitting multiple sclerosis will convert to secondary-
progressive, whereas after 25 years of the disorder, more than 90% of the individu-
als have secondary progressive multiple sclerosis [14].
Prior to establishing criteria for dissemination in time and space, individuals 
may present with clinically isolated syndrome (CIS) or radiologically isolated 
syndrome (RIS). Clinically isolated syndrome is defined as a clinical episode 
resembling a multiple sclerosis attack, after which there is full or partial recovery 
of neurological function [14, 20, 27]. Studies have shown that individuals with 
CIS may have an increased rate of conversion to multiple sclerosis especially 
with the presence of CSF oligoclonal bands and gadolinium enhancing lesions on 
MRI [14, 18, 20]. Incidental findings of cerebral and spinal cord plaques without 
a clinical phenotype are defined as radiologically isolated syndrome (RIS). In a 
5-year study of 451 patients with RIS, 34% of individuals developed a clinical 
event for which 9.6% were defined as primary progressive multiple sclerosis [28]. 
Interestingly, this study was able to strongly correlate the presence of cervical or 
thoracic spinal cord lesions with the first clinical event [28]. With this increase 
risk of progression to multiple sclerosis, the utility of disease-modifying therapies 
and longitudinal monitoring of CIS and RIS has become a priority for clinicians.
1.4 Inflammation in multiple sclerosis
The direct cause of multiple sclerosis still eludes the scientific community; 
however, several hypotheses have emerged which have been utilized to develop 
disease-modifying therapies (DMTs) and alter the course of disease. Traditionally, 
multiple sclerosis has been considered a demyelinating disease of the white mat-
ter tracts leading to peripheral symptomatology with an underlying autoimmune 
cause. Recently, demyelination located in the cerebral cortex and deep gray matter 
has emerged as a marker of progressing neurological disability [13, 29, 30]. Damage 
seen to the CNS with infiltration of immune cells suggests the role of peripheral 
immune response leading to damage of the blood brain barrier prior to established 
demyelination. Peripheral inflammation in this case may be a result of a foreign 
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pathogen (virus), autoimmune activation, or a combination of multiple events. 
Malpass [31] characterized the term “outside-in” based on evidence of cortical 
inflammation originating in the subarachnoid space in multiple sclerosis patients 
which transitioned into the white matter [32]. This further strengthens the argu-
ment for modulation of the peripheral inflammatory response which is facilitating 
early multiple sclerosis disease through activation of CD4 T lymphocytes. Once 
within the CNS, regional activation of microglia, astrocytes and macrophages 
occurs through expression of cytokines and chemokines from infiltration of T lym-
phocytes [13, 29, 30, 33]. Activation of specific subsets of CD4 lymphocytes dictates 
which cytokines are released. Pro-inflammatory cytokines are expressed after direct 
activation of Th1 and Th17 cells, whereas anti-inflammatory cytokines are a product 
of Th2 and T-regulatory cells [34–36]. Histopathology of the CNS white matter 
plaques has shown an abundance of macrophages, CD8, CD4 T lymphocytes, and B 
lymphocytes [13, 29, 30, 35]. Over time, the prolonged inflammation and infiltra-
tion of T and B lymphocytes leads to a disruption of the axonal-glial interaction 
which results in an increase in gray matter atrophy and axonal loss with marked 
demyelination [13, 29]. During the remission phase following each flare, there is 
some evidence to suggest a possible role for regulatory T cells with the induction 
of Foxp3 [37]. It is possible that during remission, a baseline level of inflammation 
is present; however, the expression of specific phenotypes of T lymphocytes shifts 
toward anti-inflammatory/regulatory rather than pro-inflammatory mechanisms. 
Based on these observations, vitamin D has emerged as a potential homeopathic 
regulator of immune cell function [2, 3, 38].
1.5 Current disease-modifying therapies
Currently, there is no definitive treatment for multiple sclerosis. Most approved 
therapies are focused on controlling peripheral inflammation and preventing 
migration across the blood brain barrier thereby reducing the incidence of acute 
flares [13, 30, 39, 40]. A majority of these therapies are administered orally, as an 
injection or through an infusion. With both invasive and non-invasive methods, 
side effects include increases in liver enzymes, injection site reactions, nausea, diar-
rhea, and most importantly, progressive multifocal leukoencephalopathy (PML) 
[39]. The primary therapies prescribed at our institution are Copaxone®, Gilenya®, 
and Tecfidera®. Copaxone®, glatiramer acetate is an immunomodulator that is 
FDA approved to reduce the frequency of relapses. Gilenya®, fingolimod, is also 
an immunomodulator that targets reduction in the number of relapses more than 
progression of disease. Tecfidera®, dimethyl fumarate, is a combination of fumaric 
acid esters that was originally approved for oral treatment of psoriasis. Because of 
the inconsistent or incomplete outcomes from treatment, as well as the evolving 
nature of the disorder, other biotherapies have been used as adjuvants.
1.6 Enkephalins as therapeutic treatment
One alternative biotherapeutic is the use of low doses of naltrexone (LDN), an 
opioid receptor antagonist. LDN is often used as an adjuvant to disease-modifying 
therapy to target fatigue associated with either the disorder or the medication. 
LDN has a strong profile of safety and tolerability [41–44]. Pilot studies utilizing 
LDN demonstrated that MS patients had an improvement in peripheral spasticity 
and mental health composite scores without inducing any side effects [42, 45]. In 
a retrospective analysis which compared LDN patients with LDN plus Copaxone® 
patients, there was no significant difference between the groups with respect to 
MRI, complete blood count, liver enzymes and the 25-foot walk test [44].
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A number of published studies, clinical trials and anecdotal stories have sup-
ported the use of LDN as a beneficial therapy for multiple sclerosis [41–48]. The 
mechanism of action for this general antagonist is to block the interaction of Opioid 
Growth Factor (OGF) (chemically termed [Met5]-enkephalin) from interacting 
at the nuclear-associated receptor OGFr. In addition to being a neurotransmitter, 
OGF is an inhibitory growth factor that suppresses proliferation of cells, includ-
ing T and B cells associated with autoimmune disorders. Naltrexone was initially 
developed to treat opioid use disorder and alcoholism at a dosing of 50 mg where it 
acts as an opioid receptor antagonist for mu, delta, and kappa opiate receptors. At 
a dosage less than 5 mg, LDN acts as a biotherapeutic and modulates the activity of 
endogenous enkephalins and endorphins [49, 50]. In the multiple sclerosis patient 
population, endogenous [Met5]-enkephalin (i.e., OGF) is reduced when compared 
to non-multiple sclerosis patients [51]. It is hypothesized that the reduction in 
serum levels of this inhibitory growth factor are unable to control the increase in 
T cell proliferation that occurs with immune-related flares. These T cells are the 
source of other pro-inflammatory cytokines that exacerbate the symptomatology of 
multiple sclerosis. The decreased serum levels of OGF appear to be compensated by 
low dosages of naltrexone (LDN).
1.6.1 Laboratory studies on LDN
Animal studies have been used to study both the mechanisms of LDN, as well as 
to establish the role of LDN as a biotherapy in mice with experimental autoimmune 
encephalomyelitis, an animal model of multiple sclerosis. In these studies, mice 
were immunized with antigens against myelin proteins—either myelin oligoden-
drocyte glycoprotein 35–55 or proteolipid peptides 139–151. The key component in 
the mechanistic pathway is the duration of opioid receptor blockade. This work is 
detailed in animal studies [51–57]. LDN produces an intermittent blockade of OGFr 
preventing OGF from binding and thereby increasing cellular replication, similar to 
what is seen with high doses of Naltrexone (HDN) through a prolonged blockade of 
OGFr [49]. Conversely, after the blockade has subsided, within 4–6 h, there is over 
proliferation of endogenous OGF and OGFr and a resulting exaggerated expression 
of p16 and p21 leading to promotion of cellular senescence [49].
A newly discovered pathway involves the antagonism of Toll-like receptor 4 
(TLR4) by LDN as means to reduce neuroinflammation or persistent pain [58, 59]. 
Specifically, activation of Toll-like receptor 4 (TLR4) initiates the release of inflam-
matory cytokines: interleukin 1 (IL-1), tumor necrosis factor α (TNFα), nitric oxide 
(NO), and interferon β (IFNβ) [48, 60]. Currently, the relationship of the Toll-
like receptor pathway to pro-inflammatory cytokine activation is not completely 
understood.
1.6.2 Clinical studies on LDN
Several studies have been conducted to evaluate multiple sclerosis patients who 
are prescribed LDN. The use of enkephalins, particularly OGF, has been demon-
strated to be safe and tolerable in Phase I and Phase II studies of pancreatic cancer 
[61, 62]. LDN is widely used for treatment of other autoimmune disorders including 
Crohn’s disease [63] and fibromyalgia [64].
1.6.3 Clinical studies on LDN and multiple sclerosis
Clinical trials using LDN for multiple sclerosis were conducted more than 
a decade ago, and most likely because it is widely used with no side-effects, 
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government agencies are reluctant to support new trials. Three clinical trials have 
suggested that LDN increased the quality of life of patients with relapse-remitting or 
secondary progressive multiple sclerosis, without serious adverse effects [42, 43, 45]. 
Two retrospective studies examining charts of patients prescribed LDN alone, as 
well as in combination with the disease-modifying therapy Copaxone®, revealed no 
exacerbation of the disease or any substantial side effect for patients in either cohort 
[44]. In this study, the average length of disease was 14 years, with an average of 
3 years on LDN alone. Clinical laboratory data revealed that patients on LDN alone 
had no significant differences in their blood chemistry, nutrition or liver data from 
patients on disease-modifying therapies.
However, these studies did not measure serum enkephalins, endorphins, or 
cytokines in an effort to gain more information on the mechanism of action for 
this biotherapeutic. A small study obtained stored serum from relapsing-remitting 
multiple sclerosis subjects and reported that enkephalin (i.e., OGF) levels were 
depressed relative to controls [51]. In the few individuals on LDN alone, serum 
OGF levels were elevated 2-fold in comparison to multiple sclerosis subjects on 
Copaxone® alone, suggesting that LDN may be effective at restoring serum enkeph-
alin. Given this information, studies on both the mouse model of EAE and multiple 
sclerosis have been pursued to evaluate select cytokines that may be dysregulated 
in multiple sclerosis and possibly modulated by LDN (and enkephalin levels) and 
restored to normal levels.
2. Clinical study: enkephalin regulation of IL-17 in multiple sclerosis
A retrospective clinical study was designed to examine serum levels of cytokines 
and endogenous peptides, including [Met5]-enkephalin.
2.1 Methods
Patients were identified through the Institute of Personalized Medicine at the 
Pennsylvania State University College of Medicine and had a clinically definitive 
diagnosis of relapsing–remitting multiple sclerosis [17, 18, 21, 36]. Selected indi-
viduals were between 18 and 70 years of age, of which 17 were males and 36 were 
females. Cohorts were established based on the disease-modifying therapy each of 
these patients was receiving. The five groups included multiple sclerosis patients 
receiving dimethyl fumarate, glatiramer acetate, low-dose naltrexone, or no 
disease-modifying therapy and a control group of non-multiple sclerosis patients. 
The 13 non-multiple sclerosis patients were recruited from the Neuroscience 
Institute and were age and gender matched to the study population. All patients 
were de-identified to the study team.
Blood was collected and stored in non-heparinized ethylenediaminetetraacetic 
acid (EDTA) tubes to prevent formation of a clot [65, 66]. Whole blood was centri-
fuged at 4°C for 10 min at 2500 rpm [65, 66]. Serum was aliquoted and stored long 
term at −80°C in 200 μL vials to prevent repeated freeze and thaw cycles.
Serum was analyzed using commercially produced sandwich or competitive 
enzyme labeled immunosorbent assay (ELISA). Opioid growth factor (MBS990622), 
β-endorphin (MBS770600), IL17A (MBS00565) and IL17 (MBS772095) ELISA kits 
were manufactured by MyBioSource (San Diego, CA); whereas the TNFα ELISA kit 
(EK0525) was purchased from BosterBio (Pleasanton, CA). Assays were completed 
following the manufacturer’s recommendations; all samples and standards were run 
in duplicate and averaged for the data analyses. Chemiluminescence was measured 
using a BioTek microplate spectrophotometer and Gen5 software at 450 nm.  
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To ensure redundancy and reproducibility, duplicate samples were run on multiple 
ELISA kits from the same manufacturer.
Data analysis was performed using GraphPad Prism 8.0 software. Parametric 
data were analyzed using one-way analysis of variance (ANOVA) with post-hoc 
comparisons made using Newman-Keuls. Correlations were determined using 
Pearson’s Correlation Coefficient (R). Significance was determined with a p value 
less than 0.05.
2.2 Results
A cohort of 53 patients was analyzed in this study, 40 of whom were individuals 
with an established diagnosis of relapsing-remitting (RR) multiple sclerosis and 13 
who did not have multiple sclerosis. Patients with multiple sclerosis who received no 
disease-modifying therapy were designated as controls along with the 13 individu-
als with no diagnosis of multiple sclerosis. Within the control population, 17 were 
females and 7 males, whereas the study population had 19 females and 10 males. 
The age distribution between the cohorts of patients on treatment ranged between 
25 and 69 years of age while the control cohort ranged in age from 25 to 78 years. 
Length of disease in the multiple sclerosis patient group was similar between the 
no-drug, dimethyl fumarate and LDN group which had mean lengths of 14.3, 10.4 
and 16.5 years, respectively.
Serum OGF levels differed substantially between multiple sclerosis patients 
who declined therapy and control subjects considered non-multiple sclerosis 
(Figure 1A). OGF levels were more than three-fold higher in non-multiple sclerosis 
cohort relative to the no-drug cohort (93 ± 26 pg/ml). Because there is no diagnosis 
provided for the no-drug volunteers, it is difficult to more fully assess these data. 
Mean serum levels for RR-multiple sclerosis subjects prescribed disease-modifying 
therapy were comparable to serum values for the no-drug cohort, and signifi-
cantly less than serum values for the non-multiple sclerosis cohort (Figure 1B). 
RR-multiple sclerosis patients receiving dimethyl fumarate had serum OGF values of 
125 ± 22 pg/ml whereas those individuals receiving glatiramer acetate had serum lev-
els of 136 ± 30 pg/ml. RR-multiple sclerosis subjects receiving LDN had mean OGF 
serum levels of 217 ± 29 mg/ml; these values did not differ from the non-multiple 
sclerosis cohort. Correlations between serum OGF levels and age or length of disease 
for cohorts of no drug, DMTs, or LDN are presented in Figure 2A and B, respec-
tively. The association between age and serum OGF had an overall significance, 
with dimethyl fumarate subjects revealing a corresponding decrease in OGF serum 
values with increasing age (p = 0.03). Regarding the length of disease, RR-multiple 
sclerosis subjects taking LDN had comparable OGF serum values irrespective of 
having disease for 2 months or 33 years (Figure 2B). RR-multiple sclerosis subjects 
not taking any drugs (no-drug cohort) also displayed a biphasic response, suggesting 
that length of disease does not impact OGF serum. Analyses of OGF serum values by 
gender indicated that females had a pattern similar to that in Figure 1B. A majority 
of the males in this study received dimethyl fumarate and had serum OGF levels that 
ranged from 25 to 200 pg/ml; the small number of male subjects in the other cohorts 
prevented data analyses.
Serum β-endorphin levels were also measured in three cohorts of RR-multiple 
sclerosis subjects and non-multiple sclerosis subjects. Levels of serum β-endorphin 
ranged between ~1 ng/ml (no-drug and dimethyl fumarate cohorts) to the mean 
of 2.3 ng/ml (non-multiple sclerosis cohorts); individual samples ranged as high 
as 4 ng/ml in the non-multiple sclerosis cohort. Despite the variation, signifi-
cant two-fold increases were recorded for non-multiple sclerosis and glatiramer 
acetate cohorts relative to no drug and dimethyl fumarate RR-multiple sclerosis 
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individuals. Associations between age and β-endorphin revealed that endorphin 
levels were relatively stable within the population of RR-multiple sclerosis subjects 
on DMT.
With regard to serum levels of inflammatory cytokines, expression levels of two 
cytokines in serum are presented in Figure 3. Serum levels of IL-17 (A) and TNFα 
(B) were measured in RR-multiple sclerosis subjects on DMTs, LDN, or no-drug, 
as well as non-multiple sclerosis controls. Mean IL-17A (not shown) concentrations 
ranged from 27 ± 3 pg/ml (dimethyl fumarate) to 39 ± 10 pg/ml (glatiramer acetate 
group). Only one sample of blood from RR-multiple sclerosis patients on LDN was 
assayed; serum IL-17A value was 46 pg/ml. No differences in serum levels were 
noted between any therapeutic treatment and controls. IL-17 levels ranged from the 
mean 0.12 ng/ml recorded for non-multiple sclerosis cohort to 0.92 ± 0.35 ng/ml for 
the dimethyl fumarate group (Figure 3A); levels of the IL-17 cytokine recorded for 
these subjects differed significantly from glatiramer acetate and no-drug cohorts. 
RR-multiple sclerosis patients had a mean IL-17 cytokine level of near 0, whereas 
some individuals using dimethyl fumarate had more than 3 pg/ml IL-17 levels.
Figure 1. 
Scatterplots of serum OGF levels (pg/ml) in (A) control subjects who were either non-multiple sclerosis 
subjects or (B) RR-MS patients who were not receiving any therapy (no drug) or RR-multiple sclerosis patients 
receiving dimethyl fumarate, glatiramer acetate, or low dose naltrexone (LDN). One-way ANOVA or t-tests 
were used to show the differences between groups. Significantly different from non-multiple sclerosis values at 
p < 0.01 (**).
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Non-multiple sclerosis and RR-multiple sclerosis patients not taking any DMT 
had comparable TNFα values (16 ± 10 and 22 ± 3 pg/ml, respectively) (Figure 3B). 
RR-multiple sclerosis cohorts on DMTs had TNFα serum values that were at least 
6-fold higher and differed significantly from the non-multiple sclerosis levels. 
Correlation analyses indicated that OGF (Figure 4A) and IL-17A (Figure 4B) were 
positively associated (R = 0.82), whereas TNFα values did not correlate (R = 0.20) 
with OGF serum values.
2.3 Discussion and summary
Cohorts of RR-multiple sclerosis patients on disease-modifying therapy, as well 
as a group of individuals diagnosed with RR-multiple sclerosis and taking LDN 
only were compared with control volunteers. in an assessment of peripheral serum 
levels of two endogenous neuropeptides—OGF (chemically termed methionine 
enkephalin) and β-endorphin, as well as 3 cytokines that are known to be involved 
Figure 2. 
Expression levels of serum OGF (pg/ml) measured by ELISA as a function of the age (years) of subject (A) or 
the length of disease (years) (B). Correlations were determined by Pearson’s Correlation Coefficient (R) tests.  
P values less than 0.05 were considered significant.
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in RR-multiple sclerosis, specifically IL-17, IL-17A, and TNFα [67–71]. Inclusion cri-
teria restricted our analyses to RR-MS subjects to those receiving glatiramer acetate 
or dimethyl fumarate. A few RR-multiple sclerosis subjects in this study were only 
prescribed LDN as an off-label product.
The restricted access to blood samples and corresponding patient data in this 
retrospective study limited the findings, as did inclusion of RR-multiple sclerosis 
patients on no drug. No rationale was reported in the REDCap database to explain 
why the RR-multiple sclerosis patients had denied therapy. It is conjured that some 
multiple sclerosis patients who have stabilized over a long period of time request to 
be removed from therapy.
The focus of this study was to determine the relationship between serum expres-
sion levels of endogenous neuropeptides, specifically OGF, and a select group of 
pro-inflammatory cytokines. OGF levels in the serum of RR-multiple sclerosis sub-
jects declined with age and were not associated with the length of disease. In gen-
eral, the OGF levels of RR-multiple sclerosis patients using DMTs, or those on no 
therapy, were substantially lower than RR-multiple sclerosis subjects on LDN. This 
relationship between OGF and RR-multiple sclerosis has been reported previously 
[51], suggesting that the biotherapeutic LDN treatment is producing enkephalins. 
Clinical studies have reported that LDN treatment resulted in perceived increased 
Figure 3. 
Scatterplots of serum cytokines IL-17 (A) and TNFα (B) measured by ELISA tests (pg/ml) in RR-multiple 
sclerosis patients receiving DMTs or no drug; controls include volunteer non-multiple sclerosis subjects. Data 
was analyzed using one-way ANOVA with subject comparisons made by Newman-Keuls tests. Significantly 
different at p < 0.05 (*) and p < 0.01 (**).
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quality of life [42, 43] and stabilization of disease symptomatology [44]. A second 
neuropeptide, β-endorphin, is known as the “feel-good” hormone and has been 
reported to increase during exercise and pregnancy [72] and to increase during 
multiple sclerosis remission [73]. In this study, β-endorphin levels were comparable 
in all subjects suggesting that these RR-multiple sclerosis patients had stabilized 
endorphins. Based on the scatter gram plots of individual expression levels of 
endorphin, some of the individuals in the glatiramer acetate group may have been 
in remission. Moreover, whereas OGF levels fluctuate with RR-multiple sclerosis 
and different therapies, β-endorphin does not appear to be altered by DMTs in 
RR-multiple sclerosis.
The proinflammatory cytokine IL-17 may be a prime indicator of RR-multiple 
sclerosis progression [69, 71]. The IL-17 family of cytokines is produced by CD4+ 
T-helper cells known as Th17 cells. At least 7 polymorphisms have been identified, 
with IL-17A and IL-17F most frequently associated with neutrophils activation in 
Figure 4. 
Associations of cytokine expression between IL-17A (pg/ml) and OGF (pg/ml) (A) or TNFα (pg/ml) and 
OGF (B) for RR-multiple sclerosis subjects receiving a DMT. Data were analyzed by Pearson’s Correlation 
Coefficient (R) tests. P values less than 0.05 were considered significant.
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autoimmunity [67, 69]. IL-17A has been identified in the CNS following migration 
of Th17 cells in response to a pro-inflammatory event [74]. Clinical studies have 
reported that IL-17A may be responsible for breakdown of the blood-brain barrier 
facilitating the entrance of other inflammatory cytokines into the CNS [71]. 
IL-17A has been shown in preclinical studies to accelerate glial activation leading 
to neuroinflammation and neurodegeneration [68]. Thus, it would be expected 
that IL-17A levels may be lowest in RR-multiple sclerosis individuals who are in 
remission or most responsive to therapy [67]. Moreover, recent preclinical studies 
have reported that both IL-17A and IL-17F increase pro-inflammatory cytokine 
IL-6 secretion [70].
In the present study, TNFα, a proinflammatory marker has been shown to 
increase in RR-multiple sclerosis [75, 76] and to be consistently elevated regard-
less of the status of disease type (i.e., clinically isolated syndrome, primary 
progressive, or relapsing-remitting), with serum levels 40–50% higher in multiple 
sclerosis subjects relative to controls. Preclinical studies have reported an associa-
tion between TNFα and impaired memory in mice with EAE [77] and implicated 
astrocyte signaling as the downstream target of overexpression of the cytokine. 
Despite studies whereby TNFα knockdown mice had more severe EAE [69] and 
therapeutic administration of the cytokine protected against the disease [74], this 
cytokine is reported to be a major contributor to cognitive deficits related to late 
stages of multiple sclerosis. In the present study, age, gender, number of relapses, or 
length of disease had no effect of TNFα levels, but in general, the expression levels 
of this cytokine were elevated in RR-multiple sclerosis subjects relative to cohorts of 
RR-multiple sclerosis patients presumably in remission or non-multiple sclerosis.
LDN is an off-label therapeutic used in substantially lower dosages than pre-
scribed for drug overdose or alcohol use (3 vs. 50 mg). Its use is increasing world-
wide [78, 79] and is consistently reported to be well-tolerated over extended periods 
of time [46]. Small clinical trials have reported few, if any, side effects [42, 43]. In 
this study, OGF serum levels appear to be correlated with IL-17A. Alternatively, 
whereas β-endorphin has been associated with the propensity to avoid alcohol or 
opioids, it was not related to RR-multiple sclerosis. The serum levels of cytokines 
IL-17A and TNFα did not appear to be discriminating biomarkers at least with the 
current population of RR-multiple sclerosis subjects. Perhaps with additional study, 
and possibly other DMTs, these cytokines will be able to discern progression of 
disease.
3. Conclusions
In summary, the preclinical and clinical data illustrate that enkephalin levels 
(i.e., OGF) are decreased in animals with EAE and humans with relapsing remitting 
multiple sclerosis. LDN as a biotherapy is associated with elevating enkephalins 
and from all aspects, appears to reduce symptomatology of multiple sclerosis. 
LDN therapy to upregulate the body’s own production of enkephalins has been 
shown by a number of clinical trials to be a safe adjuvant, or primary, treatment 
for RR-multiple sclerosis. LDN continues to be associated with stabilizing multiple 
sclerosis and does not appear to interfere with other disease-modifying therapies. 
Whether enkephalin levels directly or indirectly alter the therapeutic pathways 
is unclear at this time. Moreover, it is difficult to determine at this point whether 
specific disease-modifying therapies are more advantageous for manipulating 
enkephalin levels. However, it is evident that restored serum enkephalin expression 
is associated with reduced inflammatory cytokines and better patient outcome. 
Moving forward, studies will be conducted to determine the mechanistic role of 
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OGF in modulating both pro and anti-inflammatory cytokines. Collectively the data 
from published studies as well as the new data presented in this report demonstrate 
that the biotherapeutic LDN and resulting enkephalin (specifically OGF) levels play 
a role in disease progression of multiple sclerosis. By integrating animal model work 
and patient serum analysis, future studies will try and understand the role of OGF 
during initiation of disease and definitive diagnosis of disease. The efficacy of LDN 
alone needs to be evaluated in prospective, randomized, controlled studies, but 
unfortunately this design is not forthcoming as most physicians will prescribe the 
off-label drug based on its safety record.
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